Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | F2R | P25116 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30729659 | 0.87 | HSD17B10 (0.62) | HSD17B10SMN1; SMN2KMT2AMEN1RXFP1 | |
| SCHEMBL20152029 | 0.86 | HSD17B10 (0.61) | HSD17B10SMN1; SMN2KMT2AMEN1RXFP1 | |
| SCHEMBL4820385 | 0.86 | HSD17B10 (0.61) | HSD17B10SMN1; SMN2KMT2AMEN1RXFP1 | |
| SCHEMBL12812735 | 0.86 | HSD17B10 (0.61) | HSD17B10SMN1; SMN2KMT2AMEN1RXFP1 | |
| SCHEMBL4003494 | 0.86 | HSD17B10 (0.61) | HSD17B10SMN1; SMN2KMT2AMEN1RXFP1 | |
| SCHEMBL26464127 | 0.86 | HSD17B10 (0.61) | HSD17B10SMN1; SMN2KMT2AMEN1RXFP1 | |
| SCHEMBL11866935 | 0.85 | SMN1; SMN2 (0.63) | SMN1; SMN2LMNAKMT2AMEN1RXFP1 | |
| SCHEMBL6429391 | 0.84 | HSD17B10 (0.64) | HSD17B10SMN1; SMN2KMT2AMEN1RXFP1 | |
| SCHEMBL13255714 | 0.84 | HSD17B10 (0.59) | HSD17B10SMN1; SMN2KMT2AMEN1RXFP1 | |
| SCHEMBL17896778 | 0.84 | HSD17B10 (0.62) | HSD17B10SMN1; SMN2KMT2AMEN1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752617-B2 | Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-08-25 | — | — | US | claimed |
| EP-3233836-B1 | INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RES & DEV (FR) | 2019-01-30 | — | — | EP | claimed |
| US-11826365-B2 | Type II raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-20230242514-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-20230242514-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-11680074-B2 | Compounds, functionalised dioxaborolane or dioxaborinane derivatives, method for preparing same and uses thereof | ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS (FR) | 2023-06-20 | — | — | US | disclosed |
| WO-2022271970-A1 | METHODS AND COMPOSITIONS USEFUL FOR NUCLEIC ACID SEQUENCING | Singular Genomics Systems, Inc. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022169755-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL) BENZENESULFONAMIDES AND USES THEREOF | TRIANA BIOMEDICINES, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| EP-3464300-B1 | NOVEL COMPOUNDS, FUNCTIONALISED DIOXABOROLANE OR DIOXABORINANE DERIVATIVES, METHOD FOR PREPARING SAME AND USES THEREOF | ECOLE SUPERIEURE DE PHYSIQUE ET CHIMIE IND DE LA VILLE DE PARIS (FR) | 2021-12-01 | — | — | EP | disclosed |
| US-10752617-B2 | Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-08-25 | — | — | US | disclosed |
| US-20110065700-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-17 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| CN-101663262-A | N- (3-benzyl) -2, 2- (diphenyl) -propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases | BRISTOL MYERS SQUIBB CO | 2010-03-03 | — | — | CN | disclosed |
| US-7550458-B2 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| WO-2003043630-A1 | SOLID PHARMACEUTICAL COMPOSITION COMPRISING 4-CYANO-TRIFLUORO-3-(4-FLUOROPHENYL SULPHONYL)-2-HYDROXY-2-METHYLPROPIONO- M TOLUIDIDE, PVP, AN ANTI-OESTROGEN AND/OR AN AROMATASE INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2003-05-30 | — | — | WO | disclosed |
| US-4302599-A | Process for nitrating anilides | SCHERING CORPORATION (US) | 1981-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | PDE4A, PDE4B, PDE5A | HSD17B10 3013/4885SMN1; SMN2 3416/4885LMNA 4118/4885 |
| US-11680074-B2 | Compounds, functionalised dioxaborolane or dioxaborinane derivatives, method for preparing same and uses thereof | RDX, XDH, NOX4 | HSD17B10 1150/4885SMN1; SMN2 3745/4885LMNA 1743/4885 |
| US-20110065700-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | CYP4X1, HAX1, JAK2 | HSD17B10 2045/4885SMN1; SMN2 3292/4885LMNA 3699/4885 |
| US-11826365-B2 | Type II raf kinase inhibitors | BRAF, RAF1, ARAF | HSD17B10 2379/4885SMN1; SMN2 2691/4885LMNA 3146/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | HSD17B10 1276/4885SMN1; SMN2 3609/4885LMNA 1012/4885 |
| US-10752617-B2 | Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) | RORA, RORB, RORC | HSD17B10 818/4885SMN1; SMN2 4627/4885LMNA 4400/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | HSD17B10 4567/4885SMN1; SMN2 2049/4885LMNA 4386/4885 |
| US-20230242514-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, NR1I2 | HSD17B10 692/4885SMN1; SMN2 4370/4885LMNA 4289/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | HSD17B10 1276/4885SMN1; SMN2 3609/4885LMNA 1012/4885 |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | VDR, ESRRB, NR5A1 | HSD17B10 94/4885SMN1; SMN2 4802/4885LMNA 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.